❄️ Don't miss our November Issue🌨️ 📗 Cytomegalovirus (pp71-green) in primary prostate cancer (pan-keratin red) 📑 EACR Viewpoint on clinical KRAS/RAS inhibitors & novel strategies for RAS-mutant cancers @ciccancer.bsky.social 🔓 buff.ly/NpZSen9 #NSCLC #LUAD #Hypoxia #LungCancer

📑 If you are working on the interface of hypoxia and cancer research, this may be your cup of tea! 🦮 A guide to reactive oxygen species in tumour hypoxia: measurement and therapeutic implications 🔓 buff.ly/wrD6w1r #ROS #Hypoxia #TumourMicroenvironment

Class IIa HDACs forced degradation allows resensitization of oxaliplatin-resistant FBXW7-mutated colorectal cancer ➡️ buff.ly/SZQZJaL #HDAC #Oxaliplatin #CRCSM

The IFNγ-CIITA-MHC II axis modulates melanoma cell susceptibility to NK-cell-mediated cytotoxicity 👉 buff.ly/tJzVEhb #Melanoma #MELCSM #ImmunoOnc

🚨 New EACR Viewpoint alert The rapidly growing landscape of RAS inhibitors: from selective allele blockade to broad inhibition strategies 🔓 buff.ly/05MSKU1 #RASinhibitors #TherapyResistance #CancerResearch @helloeacr.bsky.social

🗣️New meeting announced 🟨 "Cancer Metabolism"🟨 📅 It's not too late to plan ahead Submit abstracts by Jun 29 2026 ⌛️Register by Sept 7 2026 🗓️Oct 6-8 2026 🖱️https://buff.ly/s88vxNH #CancerMetabolism #Metabolism #MetabolicReprogramming #CancerResearch

Survivin and Aurora Kinase A control cell fate decisions during mitosis 👉 buff.ly/PLDmH38 #AURKA #Mitosis #CellFate

A synthetic benzoxazine dimer derivative targets c-Myc to inhibit colorectal cancer progression ➡️ buff.ly/czDTEB0 #CRCSM #CancerResearch

Aggressive prostate cancer is associated with pericyte dysfunction 👉 buff.ly/hbBYh67 🖊️ @idibell_cat @ArkaitzLab #ProstateCancer #PCSM #Pericyte

📣The joint publishing fellowship with the @EACRnews offers a remote placement at @MolOncology Get hands-on experience in scientific editing and visit the Heidelberg office ⏰Deadline Nov 7 ➡️https://buff.ly/3ZtvMe3 #PhDchat #PostDocChat #ECRchat #CancerResearch #CancerBiology

🎃 Our October issue is online👻 ❗ Read the EACR Viewpoint article by Gerlanda Vella and Maria Rescigno on the role of tumour-associated bacteria and their interplay with the tumour microenvironment in modulating cancer progression 🔓 buff.ly/xsyuvqP #Neuroendocrine #Histopathology #CancerResearch

Patient-specific pharmacogenomics demonstrates xCT as predictive therapeutic target in colon cancer with possible implications in tumor connectivity ➡️ buff.ly/OpVpLqS #Pharmacogenomics

📄 Did you know we publish EACR Viewpoints? 📣 Introduced in 2023 when Molecular Oncology became the affiliate journal of the EACR, EACR Viewpoints showcase authoritative opinions on cutting-edge topics in #CancerResearch. 🔓 You may access them here ➡️ bit.ly/4cIqPCh @FEBSnews #CancerBiology

📣 New month, new Commentary Not just a by-product: circular DNA molecules derived from V(D)J recombination are linked to worse prognosis in B-cell leukemia 🔓 buff.ly/hO4fJ9g 🖊️ @andreaventura.bsky.social #eccDNA #ecDNA

The ACCEPTance of automation: refining circulating tumor cells enumeration for improved metastatic colorectal cancer prognosis ➡️ buff.ly/XfueJAy #CTCs #mCRC #Prognosis #Oncology #CRCSM

📖 Have you leafed through our September Issue? This Issue contains recent findings on how TME changes can alter cell function and treatment outcomes. It also highlights new therapeutic opportunities based on the TME’s dynamic landscape 🔓 buff.ly/jYUuWIM #TumourMicroenvironment

Predictors of response and rational combinations for the novel MCL-1 inhibitor MIK665 in acute myeloid leukemia ➡️ buff.ly/yxF616I 🖊️ @HeckmanLab #AML #MCL1 #HemOnc

🤩 We are excited to be attending 🧠EACR Cancer Neuroscience🧠 next month 👥 Are you going? 👉 buff.ly/lTaWPhW #CancerResearch #BrainTumours #CNScancer #NeuroOncology

📣The joint publishing fellowship with the EACR @helloeacr offers a remote placement at the journal Get hands-on experience in scientific editing and visit the Heidelberg office ⏰Deadline Nov 7 ➡️https://buff.ly/3ZtvMe3 #PhDchat #PostDocChat #ECRchat #CancerResearch #CancerBiology

Adaptaquin is selectively toxic to glioma stem cells through disruption of iron and cholesterol metabolism 🔦 buff.ly/SkrGsPb #Glioma #Metabolism

📣 Don't miss our new Commentary Only the strong survive: therapeutic selective pressure drives medulloblastoma leptomeningeal metastasis 🖊️ @MSKCancerCenter @adrienne_boire #Leptomeningeal #Metastasis #Medulloblastoma

📢Call for papers 📭Submit your latest research in the field of #LiquidBiopsy ➡️Format: Research Article, Short Report or Method ➡️Details buff.ly/ATND9t1 #ACTC2025 #CTC #ctDNA #Cancer

Gut microbiota diversity is prognostic in metastatic hormone receptor-positive breast cancer patients receiving chemotherapy and immunotherapy ➡️ buff.ly/8wmhhmv 🖊️ @GroupKyte #Microbiome #GutMicrobiota #BCSM #Immunotherapy

💻If you believe that curated data = quality controlled data then check out @datadryad 🤝Thanks to our partnership, authors can now enable the open sharing & reuse of their research data 👉https://buff.ly/3BkrNqd #OpenSource #OpenAccess #OpenResearch #OpenData #OpenScience

📄 Did you know we publish EACR Viewpoints? 📣 Introduced in 2023 when Molecular Oncology became the affiliate journal of the @EACRnews, EACR Viewpoints showcase authoritative opinions on cutting-edge topics in #CancerResearch 🔓 You may access them here ➡️ bit.ly/4cIqPCh @FEBSnews #CancerBiology

Tumor-agnostic detection of circulating tumor DNA in patients with advanced pancreatic cancer using targeted DNA methylation sequencing and cell-free DNA fragmentomics 🔦 buff.ly/dsaLPGJ #Fragmentomics #ctDNA #DNAmet #DNAmethylation

The influence of ROS1 fusion partners and resistance mechanisms in ROS1-TKI-treated non-small cell lung cancer patients 👉 buff.ly/X1aoIai #ROS1 #NSCLC #Oncofusions

⚠️Did you know? 📣Molecular Oncology is an affiliate journal with Review Commons, meaning #ReviewedPreprints can be transferred directly to the journal for editorial consideration without restarting #PeerReview

⌛ Did you book your spot yet? 🧠EACR Cancer Neuroscience🧠 👇Register by Sept 15 buff.ly/lTaWPhW #CancerResearch #BrainTumours #CNScancer #NeuroOncology

🔍 We are looking for papers! 🤝 In conjunction with the @EACRnews conference on #ImmunoOncology we have an active call for papers! 📩 Submit your latest research in the field of #CancerImmunology #ImmunoOnc 👉 Find out more details buff.ly/ZDb3rO0

Adenosine-to-inosine editing of miR-200b-3p is associated with the progression of high-grade serous ovarian cancer 👉 buff.ly/FMrZvtO #HGSOC #miR200 #RNAediting

Investigating the cell of origin and novel molecular targets in Merkel cell carcinoma: a historic misnomer 🔦 buff.ly/1ZZBtJh 🖊️ @DrLitvinov #Merkelcellcarcinoma

Bridging the gap: Multi-stakeholder perspectives of molecular diagnostics in oncology 👉 buff.ly/ERfd897 🖊️ @TimonV #MolOncology #Oncology #MolecularDiagnostics

YAP1::TFE3 mediates endothelial-to-mesenchymal plasticity in epithelioid hemangioendothelioma 👉 buff.ly/r55RHc7

📣 There is still time to surf through our August Issue 💡 Find a new EACR Viewpoint on integrating temporal dynamics into cancer research by Guillaume Jacquemet @guijacquemet.bsky.social 🏄‍♀️ buff.ly/pUt8m16

📣 Have you seen our latest Commentary? SensRORing cholesterol to drive protumoral myelopoiesis 👉 buff.ly/tzuHla3 #Metabolism #Cholesterol #Myelopoiesis

Targeting of PTP4A3 overexpression sensitises HGSOC cells towards chemotherapeutic drugs 👉 buff.ly/4OGCRch #HGSOC #Chemoresistance

Olaparib synergy screen reveals Exemestane induces replication stress in triple-negative breast cancer ➡️ buff.ly/vPDXjxq #TNBC #PARPi

🔍 We are looking for papers! 🤝 In conjunction with the recent @EACRnews conference on #ImmunoOncology we have an active call for papers! 📩 Submit your latest research in the field of #CancerImmunology #ImmunoOnc 🖊️ Research Article, Short Report or Method 👉 Find out more details buff.ly/ZDb3rO0

⏳ There is still time to register and attend! ⚕️EACR Goodbye Flat Biology: ex vivo to in vivo models of cancer⚕️ 👇Register by Aug 26 💡 buff.ly/3XkCk1h #CancerModels #CancerModel #PreclinicalResearch #ModelOrganisms #TumourModels

Multi-omic characterization of consensus molecular subtype 1 (CMS1) colorectal cancer with dampened immune response improves precision medicine ➡️ buff.ly/yKCCKjU #CRCSM #PrecisionMedicine

Endoglin mediates the tumor- and metastasis-promoting traits of stromal myofibroblasts in human breast carcinomas 👉 buff.ly/2TVz9J7 #Endoglin #BCSM #Myofibroblasts

🌅Our July issue is online🌄 🔖Thematic issue on ‘Liquid Biopsy and Precision Oncology’ highlighting diverse approaches utilized in liquid biopsy research & clinical applications 🔓 buff.ly/3I7WAHM #LiquidBiopsies #ctDNA #CTC #ctDNA #CancerResearch #ClinicalOncology

ℹ️ Don't miss our new Commentary Small modifier, big decision: switching to SUMO mode adds weight to cancer stemness in mammary tumors ➡️ buff.ly/ZscdSzr #Sumoylation #CancerStemness #BCSM

EMT-associated bias in the Parsortix® system observed with pancreatic cancer cell lines 🔦 buff.ly/39cTLtl 🖊️ @KathleenClaes1 @KrisGevaert_VIB #CTCs #LiquidBiopsy

We can't believe #FEBS2025 is over - we are still hyped! 🤯Excellent line-up of speakers, amazing quality of science and 🔥poster presentation standards! 🤝We support researchers with fair & rigorous peer review so reach out if you have questions about publishing with us #FEBSCongress2025

🌟Are you joining the FEBS Press session? 💡Did you know Editors-in-Chief of the FEBS Press journals are attending #FEBS2025? 🗣Talk to them about publishing in the not-for-profit FEBS Press journals or ask them about transformational agreements allowing you to publish for free #FEBSCongress2025

🏅 Congratulations to Nils Piernitzki from INM Leibniz Institute for New Materials for winning the daily poster prize from Molecular Oncology with her poster "Artificial tumour immune microenvironments for hybrid 3D cancer cultures" #FEBS2025 #FEBSCongress2025

🏅 Congratulations to Patryk Lorenc for winning the daily poster prize from Molecular Oncology with his poster "Double functionalised silk nanoparticles for the delivery of oligotherapeutics to VEGFR overexpressing tumour microenvironment cells"👏 #FEBS2025 #FEBSCongress2025

Day 2 of the #FEBSCongress2025! We were happy to hear from our Section Editors on: Cancer metabolism & anti-tumour immunity by Prof Ricci Did you know that low-protein diet can modulate cancer progression? The epigenetic code in autophagy & cancer by Prof Baek Have you heard about oncoautophagy?